公开(公告)号：US12128069B2

公开(公告)日：2024-10-29

申请号：US15568683

申请日：2016-04-22

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Steven M. Albelda

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K16/32 ,  C12N5/0783 ,  C12N15/85 ,  A61K45/06 ,  C12N7/00

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/0011 ,  A61K39/001102 ,  A61K39/001104 ,  A61K39/001111 ,  A61K39/001112 ,  A61K39/001117 ,  A61K39/001124 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/00117 ,  A61K39/00118 ,  A61K39/001182 ,  A61K39/001184 ,  A61K39/00119 ,  A61K39/001193 ,  A61K39/39558 ,  C07K14/47 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/32 ,  C12N15/85 ,  A61K2039/5154 ,  A61K2039/54 ,  A61K2039/572 ,  A61K45/06 ,  C07K14/70578 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/035 ,  C12N5/0637 ,  C12N7/00 ,  C12N2510/00 ,  C12N2740/15043

摘要： The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.

公开(公告)号：US20240335473A1

公开(公告)日：2024-10-10

申请号：US18745733

申请日：2024-06-17

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Greg M. Delgoffe

IPC分类号： A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/17 ,  A61K38/20 ,  A61K39/00 ,  A61K39/39 ,  A61K45/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/1774 ,  A61K38/2013 ,  A61K39/00119 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C12N5/0636 ,  A61K2039/5158 ,  A61K2039/876 ,  A61K45/05 ,  A61K2800/78 ,  C12N2501/39 ,  C12N2501/999

摘要： The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1α in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1α include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods.

公开(公告)号：US12048717B2

公开(公告)日：2024-07-30

申请号：US16303828

申请日：2017-06-05

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Greg M. Delgoffe

IPC分类号： A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/17 ,  A61K38/20 ,  A61K39/00 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783 ,  A61K45/00

CPC分类号： A61K35/17 ,  A61K31/341 ,  A61K31/429 ,  A61K31/4439 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/7056 ,  A61K38/1774 ,  A61K38/2013 ,  A61K39/00119 ,  A61K39/39 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C12N5/0636 ,  A61K2039/5158 ,  A61K2039/876 ,  A61K45/05 ,  A61K2800/78 ,  C12N2501/39 ,  C12N2501/999 ,  A61K38/2013 ,  A61K2300/00

摘要： The present disclosure provides methods for expanding tumor-infiltrating lymphocytes (TILs), such as tumor-infiltrating T cells, utilizing an agonist of PGC1α in vivo, ex vivo, or both. Exhausted T cells present in the TIL population fail to effectively proliferate, produce cytokines, or kill target cells. The present disclosure provides methods to correct these defects through the use of pharmacologic agents to reprogram the metabolism of the exhausted intratumoral T cells. Exemplary agonists of PGC1α include proliferator-activated receptor (PPAR)-gamma agonists (e.g., a thiazolidinedione (TZD), aleglitazar, farglitazar, muraglitazar, or tesaglitazar), AMPK activators (e.g., 5-aminoimidazole-4-carboxamide ribonucleotide, AICAR), and sirtuin activators (e.g., resveratrol, SRT1720, SRT2104, SRT2183, SRT1460). Also provided are kits can compositions that can be used with such methods.

公开(公告)号：US12023379B2

公开(公告)日：2024-07-02

申请号：US17132320

申请日：2020-12-23

申请人： Emory University

发明人： Periasamy Selvaraj

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K39/385 ,  A61K39/0011 ,  A61K39/001102 ,  A61K39/001106 ,  A61K39/001124 ,  A61K39/001129 ,  A61K39/00117 ,  A61K39/001172 ,  A61K39/001173 ,  A61K39/001182 ,  A61K39/00119 ,  A61K39/001191 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/39 ,  A61K2039/515 ,  A61K2039/5152 ,  A61K2039/5258 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/6018 ,  A61K2039/62 ,  A61K2039/627

摘要： In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.

公开(公告)号：US20240083967A1

公开(公告)日：2024-03-14

申请号：US18236327

申请日：2023-08-21

申请人： MEDIGENE IMMUNOTHERAPIES GMBH

发明人： Christian ELLINGER ,  Carina WEHNER ,  Manon WEIS ,  Susanne WILDE ,  Dolores SCHENDEL

IPC分类号： C07K14/725 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/30

CPC分类号： C07K14/7051 ,  A61K35/17 ,  A61K39/00119 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/3053 ,  A61K2039/5154 ,  C07K2317/34 ,  C07K2317/73

摘要： The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.

公开(公告)号：US11865178B2

公开(公告)日：2024-01-09

申请号：US16759035

申请日：2018-10-25

申请人： North Carolina State University

发明人： Zhen Gu ,  Yanqi Ye

IPC分类号： A61K41/00 ,  A61P35/00 ,  A61K39/00 ,  A61K9/00 ,  A61K31/407 ,  A61K38/19 ,  A61K45/06 ,  A61K47/36 ,  A61N5/06 ,  A61N5/067

CPC分类号： A61K41/0057 ,  A61K9/0021 ,  A61K31/407 ,  A61K38/193 ,  A61K39/0011 ,  A61K39/00119 ,  A61K45/06 ,  A61K47/36 ,  A61N5/062 ,  A61P35/00 ,  A61N5/067 ,  A61N2005/0659

摘要： Embodiments of the present disclosure relate generally to photoimmunotherapy for treating cancer. More particularly, the present disclosure provides photo-responsive dermal applicators that use transdermal microneedle arrays to administer an immunogenic composition and a photo-sensitive biological pigment to a subject to treat and/or prevent cancer. Photo-responsive dermal applicators of the present disclosure provide the ability to target cancerous tumors in a manner that is safer and less invasive than conventional means.

公开(公告)号：US20230310584A1

公开(公告)日：2023-10-05

申请号：US18022778

申请日：2021-08-25

申请人： SCANCELL LIMITED

发明人： Linda Gillian Durrant ,  Mireille Vankemmelbeke ,  Victoria Anne Brentville ,  Rachael Louise Metheringham

IPC分类号： A61K39/215 ,  C07K16/28 ,  C07K16/40 ,  C07K14/005 ,  C07K14/47 ,  A61K39/00 ,  A61P31/14 ,  A61P35/00

CPC分类号： A61K39/215 ,  C07K16/283 ,  C07K16/40 ,  C07K14/005 ,  C07K14/4748 ,  A61K39/001188 ,  A61K39/001192 ,  A61K39/00119 ,  A61P31/14 ,  A61P35/00 ,  C07K2319/30 ,  C07K2317/20 ,  C07K2317/53 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/34 ,  C12N2770/20022 ,  C12N2770/20034 ,  A61K2039/53 ,  A61K2039/505

摘要： The present invention relates to nucleic acids and peptides encoded by those nucleic acids. In particular, the peptides comprise a modified IgG1 Fc region and one or more heterologous epitopes, which may be B- or T-cell epitopes. A nucleic acid of the invention may encode a polypeptide comprising: (i) a modified Fc region of a human IgG1, and (i) at least one heterologous antigen, wherein (a) the modified Fc region comprises at least the part of Fc that is capable of binding to CD64 and/or TRIM21, (b) at least one residue of the Fc region is modified to the corresponding residue from a mouse IgG3 antibody and (c) the modified Fc region has enhanced avidity for Fc-gamma receptor (FcγR) when compared to the corresponding wildtype Fc region.

公开(公告)号：US20230270832A1

公开(公告)日：2023-08-31

申请号：US17984647

申请日：2022-11-10

申请人： TScan Therapeutics, Inc.

发明人： Yifan Wang

IPC分类号： A61K39/00 ,  C07K14/47 ,  C07K14/74 ,  G01N33/569

CPC分类号： A61K39/00119 ,  C07K14/4748 ,  C07K14/70539 ,  G01N33/56972 ,  A61K2039/876

摘要： Provided herein are MAGEA1 immunogenic peptides, binding proteins recognizing MAGEA1 immunogenic peptides, and uses thereof.

公开(公告)号：US20190216910A1

公开(公告)日：2019-07-18

申请号：US16263098

申请日：2019-01-31

申请人： President and Fellows of Harvard College

发明人： David J. Mooney ,  W. Aileen Li ,  Omar Abdel-Rahman Ali ,  Ting-Yu Shih

IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K47/02 ,  A61K47/34

CPC分类号： A61K39/001106 ,  A61K9/0019 ,  A61K9/5031 ,  A61K39/00119 ,  A61K39/39 ,  A61K47/02 ,  A61K47/34 ,  A61K2039/5154 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55522 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/6056 ,  A61K2039/812 ,  A61K2039/876 ,  A61P35/00

摘要： The provided herein are methods and compositions for eliciting an immune response to an antigen, such as cancer and microbial antigens.